December 2022 PMID 35773341

Alessio David Nahmad, Eli Reuveni, Ella Goldschmidt, Tamar Tenne, Meytal Liberman, Miriam Horovitz-Fried, Rami Khosravi, Hila Kobo, Eyal Reinstein, Asaf Madi, Uri Ben-David, Adi Barzel

Download social card

Mentions

44
Peak: 4 in Jul 2022
across 5 sources since Jul 2022

Extended reach

3,223
potential audience

Total likes

8

Video views

144

Mentions per month

Jul 2022 – May 2023

Where it's discussed

  • News27 articles
  • Blogs8 articles
  • X / Twitter5 posts
  • YouTube2 videos
  • Facebook2 posts

AI synopsis

What people are saying

The social discussions are largely centered around technical concerns, such as mentions of chromosome 14 losses and the presence of aneuploidy, highlighting worries about genetic stability post-CRISPR editing. The tone is cautionary and analytical, reflecting serious consideration of the research findings' implications for future clinical use.

AgreementStrong agreement

Most discussions express concern or skepticism about the safety of CRISPR-Cas9 proceeding without further monitoring, indicating strong agreement with the negative implications highlighted.

InterestModerate interest

Participants show moderate interest, focusing on specific technical issues like chromosome loss and aneuploidy, rather than broad enthusiasm.

EngagementHigh engagement

Discussions delve into detailed implications such as chromosomal abnormalities, suggesting deep engagement with the scientific concerns raised.

ImpactHigh impact

Many discussions emphasize the potential clinical and research consequences of chromosomal disruptions, underscoring high impact.

Abstract in brief

  • This study analyzed the effects of CRISPR-Cas9 gene editing on primary human T cells, focusing on disruptions to T cell receptor (TCR) genes.
  • Researchers found chromosome 14 losses and gains, impacting TCRα, and significant truncation of chromosome 7, linked to TCRβ, leading to cell anomalies and reduced cell growth.
  • The results highlight that such chromosomal changes are common after CRISPR editing and need careful monitoring in clinical applications.

Top posts

Most liked on X and Bluesky
CRISP_SCIENCE
@ScienceCrisp · X

"Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage" Nahmad AD, Reuveni E, Goldschmidt E [..] Madi A, Ben-David U, Barzel A. (bioRxiv. 2021-08-20) Nat Biotechnol 2022-06-30. https://t.co/vRwH0ls6qC

Jul 5, 2022 · 2 likes · 1,922 followers View post →
サイエンスあれこれ
@sarekore · X

T細胞の14番染色体の標的が切断された場合、細胞の約5%で適切な修復が行われず、この染色体が失われました。2、7、14番のすべての染色体上の標的が同時に切断されると、損傷が増加し、それぞれ細胞の3%、10%、9%で切断を修復できませんでした。NatureBiotechnology誌https://t.co/uYPnlRP0Up

Jul 27, 2022 · 1 like · 922 followers View post →
S.HIROMITSU
@S_HIROMI2 · X

CRISPR-Cas9によるゲノム編集の結果生じる染色体異数性細胞の評価を行った論文。 TCRを標的にしたゲノム編集ののち、FISHやデジタルPCRによってコピー数を測定した結果、編集直後で10%弱、14日後でも1%の異数性細胞が生存していたことを報告している。 https://t.co/xUliIOCT46

Feb 27, 2023 · 1 like · 42 followers View post →
Yuta Asano
@yutaAsano1991 · X

https://t.co/H9RVPYZiUf

Jul 12, 2022 · 187 followers View post →

All mentions

S.HIROMITSU
@S_HIROMI2 · X

CRISPR-Cas9によるゲノム編集の結果生じる染色体異数性細胞の評価を行った論文。 TCRを標的にしたゲノム編集ののち、FISHやデジタルPCRによってコピー数を測定した結果、編集直後で10%弱、14日後でも1%の異数性細胞が生存していたことを報告している。 https://t.co/xUliIOCT46

Feb 27, 2023 · 1 like · 42 followers View post →
John Hickman
@JohnHic14305000 · X

https://t.co/c54j2qlJcB Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage

Dec 16, 2022 · 7 followers View post →
サイエンスあれこれ
@sarekore · X

T細胞の14番染色体の標的が切断された場合、細胞の約5%で適切な修復が行われず、この染色体が失われました。2、7、14番のすべての染色体上の標的が同時に切断されると、損傷が増加し、それぞれ細胞の3%、10%、9%で切断を修復できませんでした。NatureBiotechnology誌https://t.co/uYPnlRP0Up

Jul 27, 2022 · 1 like · 922 followers View post →
Yuta Asano
@yutaAsano1991 · X

https://t.co/H9RVPYZiUf

Jul 12, 2022 · 187 followers View post →
CRISP_SCIENCE
@ScienceCrisp · X

"Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage" Nahmad AD, Reuveni E, Goldschmidt E [..] Madi A, Ben-David U, Barzel A. (bioRxiv. 2021-08-20) Nat Biotechnol 2022-06-30. https://t.co/vRwH0ls6qC

Jul 5, 2022 · 2 likes · 1,922 followers View post →